AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice.
-
Authors
-
-
Li, Yu1
-
Xu, Shanqin1
-
Mihaylova, Maria M2
-
Zheng, Bin3
-
Hou, Xiuyun1
-
Jiang, Bingbing1
-
Park, Ogyi4
-
Luo, Zhijun1
-
Lefai, Etienne5
-
Shyy, John Y-J6
-
Gao, Bin4
-
Wierzbicki, Michel7
-
Verbeuren, Tony J7
-
Shaw, Reuben J2
-
Cohen, Richard A1
-
Zang, Mengwei8
-
1
Department of Medicine, Vascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA 02481, USA.
-
2
Howard Hughes Medical Institute, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA; Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
-
3
Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
-
4
Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA.
-
5
Lyon University, INSERM U1060, INRA U1235, CarMeN Laboratory, University Lyon-1, F- 69600 Oullins, France.
,
(France)
-
6
Division of Biomedical Sciences, University of California, Riverside, Riverside, CA 92093, USA.
-
7
Institut de Recherche Servier, 92150 Suresnes, France.
,
(France)
-
8
Department of Medicine, Vascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA 02481, USA. Electronic address: [email protected]
- Type
- Published Article
- Journal
-
Cell metabolism
- Publication Date
-
Apr 06, 2011
- Volume
-
13
- Issue
-
4
- Pages
-
376–388
- Identifiers
-
DOI: 10.1016/j.cmet.2011.03.009
-
PMID: 21459323
- Source
-
Medline
- Language
-
English
- License
-
Unknown
Abstract
AMPK has emerged as a critical mechanism for salutary effects of polyphenols on lipid metabolic disorders in type 1 and type 2 diabetes. Here we demonstrate that AMPK interacts with and directly phosphorylates sterol regulatory element binding proteins (SREBP-1c and -2). Ser372 phosphorylation of SREBP-1c by AMPK is necessary for inhibition of proteolytic processing and transcriptional activity of SREBP-1c in response to polyphenols and metformin. AMPK stimulates Ser372 phosphorylation, suppresses SREBP-1c cleavage and nuclear translocation, and represses SREBP-1c target gene expression in hepatocytes exposed to high glucose, leading to reduced lipogenesis and lipid accumulation. Hepatic activation of AMPK by the synthetic polyphenol S17834 protects against hepatic steatosis, hyperlipidemia, and accelerated atherosclerosis in diet-induced insulin-resistant LDL receptor-deficient mice in part through phosphorylation of SREBP-1c Ser372 and suppression of SREBP-1c- and -2-dependent lipogenesis. AMPK-dependent phosphorylation of SREBP may offer therapeutic strategies to combat insulin resistance, dyslipidemia, and atherosclerosis. Copyright © 2011 Elsevier Inc. All rights reserved.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 01/03/2021 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/21459323
Report this publication